Year: 2021

Third-quarter Revenue of $5.8 Million on Diversified Product Sales and Contract Revenue Sales Backlog of $14.9 Million on Strong Bookings for Military Night Vision Goggles and Medical Business Company Sets New Industry Benchmark with Full-color dPd™ Display Prototype of Over 10,000 cd/m2 Achieves Qualified Production for High-brightness XLE Displays HOPEWELL JUNCTION, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) — eMagin Corporation, or the “Company,” (NYSE American: EMAN), a leader in the development, design, and manufacture of Active-Matrix OLED microdisplays for high-resolution, AR/VR and other near-eye imaging products, today announced results for its quarter ended September 30, 2021. “eMagin has always set the standard for innovation and performance in the microdisplay industry, and in the third quarter we reached a number of important...

HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) — Deep Down, Inc. (OTCQB: DPDW) (“Deep Down” or the “Company”), a specialist in offshore energy equipment and services, today reported results for its third quarter ended September 30, 2021. Deep Down will hold a conference call today, Friday, November 12, 2021 at 10:00 am Eastern Time to review its results and outlook (call details below). Deep Down at a Glance: Share Price†: $0.74   Cash*: $3.7M  52-Week Range: $0.34 – $0.80   Book Value*: $9.1M  Shares Out.†: 12.4M   Price / Book Value: 1.0x  Market Cap†: $9.2M   TTM Revenue: $15.5M  *As of 09/30/21; †As of 11/10/21      Charles Njuguna, Deep Down’s CEO, commented, “Deep Down’s results for the third quarter of 2021 represent our continued efforts to position the company for growth while demonstrating the challenges...

Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC) Expanded FAP alpha inhibitor platform and on track to file an IND/CTA for PNT2004’s lead, PNT6555, in the first half of 2022 Completed construction and commissioning of Indianapolis manufacturing facility with first clinical product shipment expected by the end of fiscal 2021 INDIANAPOLIS, Nov. 12, 2021 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “In the last quarter, we made significant progress in the development of our next-generation...

FREDERICK, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the third quarter and first nine months of 2021. TOMI Chief Executive Officer, Dr. Halden Shane stated, “In the third quarter, we continued to add premier customers, expanded our technology solutions among our existing base of customers, launched our SteraPak and broadened our sales channels with the addition of our Amazon store. We continued to see positive signs in the marketplace and grew third quarter revenue by 50% sequentially over second quarter 2021 results. “We remain committed to allocating time and...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Nov. 12, 2021 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) released its third quarter results today. Mike Maguire, Chief Executive Officer, commented: “The market and High Arctic have reached an inflection point. Commodity prices have increased significantly, a rig is being mobilized to location in Papua New Guinea, operating hours are increasing in Canada and many customers are receptive to pricing discussions. The past 18 months have been exceptionally challenging as we dealt with the impact of the Covid-19 pandemic and an oil price collapse. I want to thank our employees and...

Interim Management Statement covering Q1 2021/22 The Board of Directors of Rovsing A/S has today considered and approved the Interim Management Statement for the first quarter (1 July 2021 – 30 September 2021) of the financial year 2021/22. Q1 highlightsIn Q1 of the financial year 2021/22, the revenue amounted to DKK 5,6 million (DKK 5,8 million in Q1 2020/21).Q1 EBITDA amounts to DKK 0,1 million (DKK 0,4 million in Q1 2020/21).Rovsing’s Q1 is traditionally a quarter with a lower activity level in our industry due to the summer vacation period.Rovsing’s market situation remains positive, with many new programmes upcoming in the industry both commercially and as well in the institutional segment, with further tenders and prospects expected during the financial year. The order backlog currently amounts to DKK 39 million, covering...

First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S.Validive® Phase 2b/3 VOICE Trial Cleared to Enroll in Europe andon Track for Reaching Interim in H1 2022 WILMETTE, Ill., Nov. 12, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced third quarter 2021 financial results and summarized recent clinical developments. Recent Clinical Developments ValidiveMonopar received clearance in multiple European countries to conduct its Phase 2b/3 VOICE clinical trial of Validive (clonidine HCl mucobuccal tablet) for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT)...

NEEDHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “With the completion of our IPO in August 2021 and multiple data readouts across our product candidates expected over the next 12 months, we are well-capitalized and in a strong position to advance on the Company’s goal to bring novel oncolytic viral immunotherapies to patients with cancer,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel Therapeutics. “In the quarter and recent weeks, we expanded visibility of our technology and clinical programs with six presentations...